Background: Patients increasingly benefit from immunosuppressive/immunomodulatory medications for a range of conditions allowing them a lifestyle similar to healthy individuals, including travel. However, the administration of live vaccines to immunodeficient patients bears the risk of replication of the attenuated vaccine microorganism. Therefore, live vaccines are generally contraindicated on immunosuppression. Data on live vaccinations on immunosuppressive/immunomodulatory medication are scarce. We identified all travellers seeking pre-travel advice in three Swiss travel clinics with a live vaccine during immunosuppressive/immunomodulatory therapy to ascertain experienced side effects. A retrospective and multi-centre study design was chosen to increase the sample size. Methods: This study was conducted in the travel clinics of the University of Zurich; the Swiss TPH, Basel; and Geneva University Hospitals. Travellers on immunosuppressive/immunomodulatory therapy who received live vaccines [yellow fever vaccination (YFV), measles/mumps/rubella (MMR), varicella and/ or oral typhoid vaccination (OTV)] between 2008 and 2015 were identified and interviewed. A total of 60 age-and sex-matched controls (matched to Basel/Zurich travel clinics travellers) were included. Results: Overall, 197 patients were identified. And 116 patients (59%) and 60 controls were interviewed. YFV was administered 92 times, MMR 21 times, varicella 4 times and OTV 6 times to patients on immunosuppressive/immunomodulatory therapy. Most common medications were corticosteroids (n = 45), mesalazine (n = 28) and methotrexate (n = 19). Live vaccines were also administered on biological treatment, e.g. TNF-alpha inhibitors (n = 8). Systemic reactions were observed in 12.2% of the immunosuppressed vs 13.3% of controls; local reactions in 7.8% of the immunosuppressed vs 11.7% of controls. In controls, all reactions were mild/moderate. In the immunosuppressed, 2/21 severe reactions occurred: severe local pain on interferon-beta and severe muscle/joint pain on sulfasalazine. Conclusion: Safety of live vaccines given to immunosuppressed patients cannot be concluded. However, it is re-assuring that in the examined patient groups no serious side effects or infections by the attenuated vaccine strain occurred.
Introduction
The use of immunosuppressive/immunomodulatory medications for a wide range of underlying conditions has been rising over the past years. Patients increasingly benefit from these therapies allowing them a lifestyle similar to healthy individuals, including travel to overseas destinations. 1, 2 Travel destinations do not differ between patients on immunosuppressive therapy and other travellers, including trips to high-risk areas. [2] [3] [4] Due to their immunosuppression, these patients are at higher risk of infectious diseases in term of infections, morbidity and mortality. [5] [6] [7] [8] [9] Consequently, immunization is particularly important for this population. However, the administration of live vaccines, such as yellow fever vaccination (YFV), to immunodeficient patients bears the risk of replication of the attenuated vaccine microorganism and clinically manifest infection. [10] [11] [12] Therefore, most international guidelines state that live vaccines are contraindicated in patients on immunosuppression, leading to challenging conditions in every day consultations of this vulnerable group of patients. [13] [14] [15] Some national recommendations, such as the Finnish ones, allow live vaccinations on non-biological immunosuppression after careful risk/benefit assessment. 16 In Switzerland, the vaccination recommendations allow live vaccinations on low-dose methotrexate (MTX). [17] [18] [19] [20] All recommendations are mostly based on expert opinion, as data are scarce. These last few years, efforts were made to evaluate the safety of some live vaccines in selected immunosuppressed individuals. In general, primary live vaccinations are potentially more dangerous than secondary vaccinations as the immune system cannot build upon an existing immune memory to deal with the attenuated vaccine strain. In contrast, a secondary live vaccine is believed to be safer as an immune memory response can be activated and avert a systemic infection.
Measles, mumps, rubella vaccination
Several studies on secondary measles, mumps, rubella (MMR) vaccinations have been published in patients with juvenile rheumatic diseases. Patients were on treatment with classical disease modifying antirheumatic drugs (DMARDs), such as MTX and/or biological therapy with tumour necrosis factor alpha (TNFα) blocking agents or interleukin 1 (IL1) receptor antagonists and vaccination was safe. [21] [22] [23] In a prospective study, 2/28 juvenile patients received a first-time MMR vaccination. 24 In one of them (therapy with MTX and corticosteroids) fever and a skin rash appeared 20 days post-vaccination. It was concluded that the rash was part of the disease activity rather than a side effect of vaccination (personal communication). Several studies reported on primary [25] [26] [27] and secondary 28 MMR vaccination in stable patients after solid organ transplantation (SOT). Only mild reactions were reported. Overall, studies in patients with autoimmune diseases and after SOT on low immunosuppressive therapies have shown no severe adverse events.
In some small studies, MMR vaccination was safely administered to children with leukaemia. 29, 30 However, in a study published in 1962, a 2-year seronegative old boy with leukaemia on treatment with MTX (dosage not specified) was vaccinated against measles; he developed pneumonia and died. 31 
Varicella
In patients with rheumatic diseases on therapy with corticosteroids, DMARDs and/or TNFα blockers, two prospective studies were performed with a first-time varicella vaccination without safety issues. 32, 33 Varicella vaccination was administered to 17 patients after kidney transplantation on therapy with prednisone, cyclosporine and azathioprine. 34 One patient developed a mild varicella rash. Several other smaller studies on varicella vaccination after SOT have been performed without any reported safety issues. [26] [27] [28] 35, 36 Most of the included patients had received a liver transplant; at the time of vaccination they had stable organ functions and were on low-dose immunosuppressive therapy.
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Yellow fever vaccination 
Oral typhoid vaccination
Oral typhoid vaccination (OTV, Tya21) is believed to be safe. More than 400 million doses have been administered worldwide (personal communication) and no single occurrence of a systemic infection has been reported despite the administration to HIV patients. 42 However, data in patients with immunosuppressive agents are not available and OTV is consequently contraindicated especially due to the availability of an inactivated parenteral vaccine.
Objectives of this study
In this study we aim to add to the published scarce numbers on live vaccines in patients on immunosuppressive/immunomodulatory therapy by: 
Rationale for study design
Live vaccinations are contraindicated on most immunosuppressive/immunomodulatory therapies and are only allowed after a careful risk/benefit assessment. Thus, patients that fulfil the inclusion criteria are infrequent. A retrospective and multi-centre study design was consequently chosen to increase the sample size.
To overcome recall bias in the patient group we included an age-and sex-matched control group of travellers without immunosuppressive/immunodulatory therapy who received the respective live vaccine in the same time period.
For some medications, it is well accepted that live vaccines may be given; one example is long-term low-dose corticosteroid therapy. However, 'low-dose' is defined differently from country to country, the threshold is, for example, 20 mg prednisone or equivalent in the USA, Switzerland and Germany vs 10 mg in France and UK. 43 In the Netherlands the decision on whether live vaccines may be given is based on the cumulative prednisone dose. MTX is another example. The thresholds have been mainly based on expert opinion and lack solid data. For this reason, we decided to include also travellers vaccinated on low-dose corticosteroid therapy and other generally accepted medications. 
Methods

Study location and time frame
Data collection
Before the travel consultation, all individuals completed a form (electronic at ZRM, paper format at Swiss TPH and HUG) including demographic information, details on the planned trip and data on their medical history including taken medications. Physicians verified the information during the consultation and added information on pre-existing medical conditions, used medications and prescribed vaccinations during the current consultation. As a first step, these forms were searched for all travellers on immunosuppressive/immunomodulatory medications (search terms in Box 1). In Basel and Geneva the search was performed manually. In Zurich, several collected data variables were searched electronically for the usage of an immunosuppressive/ imunomodulatory medication. Amongst travellers detected by this search, those who received a live vaccine (MMR, varicella, YFV and/or OTV) were identified. Herpes Zoster vaccine was not available in Switzerland during the time period and thus could not be looked at in this study.
The identified patients were contacted by telephone and asked the questions from a pilot-tested questionnaire. If the patients could not be reached by telephone they were contacted by E-mail. The questionnaire was developed with the input from several European vaccination and travel medicine experts during meetings of the European Network for Tropical Medicine and Travel Health (TropNet) and consecutive postmeeting electronic correspondence. The following information was gathered: visit date, age, sex, types of received vaccinations, underlying condition(s) for immunosuppressive/immunomodulatory treatment, kind of immunosuppressive/immunomodulatory medication and dosage, time between the last dose of immunosuppressant before vaccination, reactions after the vaccination in the graduation mild (not interfering in daily activities), moderate (interfering with daily activities, but able to perform daily activities) and severe (not able to perform daily activities), serious adverse reactions (death, life-threatening, persistent or significant disability or incapacity, hospitalization or prolongation of existing inpatient hospitalization, congenital anomaly or birth defect, other important medical event or reaction), actions taken due to vaccine reaction.
While live vaccines are generally contraindicated under immunosuppressive therapy, 'adequate' time intervals (between cessation of an immunosuppressive medication and the administration of a live vaccine) have been defined after which the administration Box 1. Search terms Classic immunosuppressant/DMARDs/classic anti-cancer medication:
azathioprine, chlorambucil, ciclosporin, cladribine, colchicine, corticoid, cortisone, cyclophosphamide, cyclosporine, dimethyl fumarate, everolimus, fludarabine, glucocorticoid, hydroxychloroquine, leflunomide, melphalan, mesalamine, mesalazine, methotrexate, mitoxantrone, MTX, mycophenolate mofetil, pentostatin, prednisone, prednisolone, rapamycin, salazopyrin, sirolimus, steroid, sulfasalazine, tacrolimus, teriflunomide, thalidomide, thiopurine, 5-aminosalicylic acid (5-ASA), 6-mercaptopurine general terms: calcineurin inhibitor, DMARD Biologicals/immunomodulators: abatacept, adalimumab, alefacept, alemtuzumab, anakinra, basiliximab, belatacept, belimumab, certolizumab, daclizumab, eculizumab, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta, natalizumab, ocrelizumab, ofatumumab, pimecrolimus, rituximab, tocilizumab, ustekinumab general terms: biological, TNF, IL-1Ra antagonist, anti-CD20, RTX, CTLA-4 antagonist, IL-6 antagonist Brand names: actemra, alkeran, amevive, arava, arzerra, asacol, asazine, aubagio, avonex, benlysta, cellcept, certican, chloroquin, cimzia, copaxone, elidel, enbrel, endoxan, gilenya, humira, imurek, kineret, lemtrada, leukeran, leustatin, litak, mabthera, myfenax, myfortic, nivaquine, novantron, nulojix, orencia, pentasa, plaquenil, prograf, puri-nethol, rapamune, rebif, remicade, ristova, salofalk, sandimmun, simponi, simulect, soliris, stelara, tecfidera, tysabri, xaluprine, zenapax of a live vaccine is considered safe. These time intervals differ between medications and depend on the drug's half-life and other factors. 'Adequate' time interval means a sufficient interval time between drug interruption and live vaccine immunization, while the term 'critical' time interval is used when a live vaccine was given before the 'adequate' time interval had elapsed. L.G. Visser's publication 'The immunosuppressed Traveler' was used 44 as reference to define 'adequate' time intervals. If the respective medication was not mentioned in the publication, the 'adequate' time intervals as defined by the Swiss Federal Office of Public Health (FOPH) 18 were applied. In patients on corticosteroids, we differentiated between short-term (<2 weeks) and long-term (≥2 weeks) use.
In the following sections of this article the term 'immunosuppressive' will include both 'immunosuppressive and immunomodulatory' therapy.
In Zurich and Basel, a healthy age-and sex-matched control group was enroled. For logistical reasons, in Geneva, the inclusion of controls was not feasible. Healthy controls (HC) had to fulfil the following inclusion criteria: no immunosuppressive therapy, sex-and age-matched, same live vaccination, the live vaccination was administered at the same time point (±6 months), HCs were contacted in the same way as patients. Comparative analyses were performed between immunosuppressed patients in Basel/Zurich (BS/ZH immunosuppressed) vs matched HCs.
Statistical analysis
Frequencies and percentages of categorical variables were compared using Chi-squared or Fisher's exact tests as appropriate. Means, standard deviations (SD), medians and interquartile ranges (IQR) were reported and two-group comparisons were carried out using T-tests or Wilcoxon-Mann-Whitney tests as appropriate. All analyses were performed anonymously using Stata 13.1 (Stata Corp. LP, TX, USA).
Results
Across the three travel clinics, 197 travellers on immunosuppressive therapy received a live vaccine and 116 could be interviewed for the assessment of adverse reactions (Figure 1) . A total of 60 non-immunosuppressed controls matched to the participants from the Basel and Zurich travel clinics were interviewed.
Demographics
Contacted immunosuppressed individuals were on a mean 45.3 years (SD: 15.9) old and 57 (49.1%) were males. HCs had a comparable age (46.2 years, SD: 15.4) and sex distribution [n = 30 (50.8%) controls were males] to Basel/Zurich travel clinic patients (average: 45.7 years, SD: 15.4; 31 (51.7%) males.
In the immunosuppressed patients the most common underlying diseases were rheumatic conditions (n = 40, 34.5%) and inflammatory bowel diseases (n = 33, 28.4%, Table 1 ).
Overall, 92 vaccinations against yellow fever, 21 against MMR, 4 against varicella and 6 OTVs were given to patients on immunosuppression. None received a sole measles vaccination (Table 2) . Controls received 48 YFVs, 14 MMR vaccinations, 4 OTVs and 3 varicella vaccinations.
Percentages of participants who had previously received the respective administered live vaccination were comparable between immunosuppressed BS/ZH travellers and controls for YFV, mumps and rubella vaccines (data not shown). However, 90.0% of controls had received a previous measles vaccinations compared to 41.7% of immunosuppressed BS/ZH patients (P = 0.031).
Most common medications across all immunosuppressed participants were corticosteroids (n = 45). In all immunosuppressed travellers, the prednisone equivalent dosage was 7.5 mg/day on a median, IQR: 5-20 mg/day; for long-term (≥2 weeks) use: 7.5 mg/ day, range: 1.25 mg-80 mg/day; and for short-term use (<2 weeks): 45 mg a day, range: 5 mg-840 mg a day. Four patients (two patients with 20 mg/day, one 50 mg/day and one with 80 mg/ day) with long-term therapy were above the 'permitted' maximum of ≥20 mg/day prednisone dose per day according to the Swiss vaccination recommendations. 18 The second most frequent drug was mesalazine (n = 28), followed by MTX (n = 19, weekly dose: median 12.5 mg, IQR: 10-20 mg), with two patients treated with weekly MTX-dosages above 20 mg, one with 22.5 mg and one with 100 mg. In the patient with a weekly dosage of 100 mg, the last MTX-intake was 4 days before re-vaccination against yellow fever. The other patient had received YFV outside the 'critical' time interval.
Live vaccines were also given on biological therapies, such as TNF-alpha inhibitors (n = 8 travellers, Table 2 ).
All but five patients were on current immunosuppressive therapy (or in 'critical time interval' after cessation/pausing of an immunosuppressive medication). In five travellers, adequate time intervals had elapsed since the last treatment dose was taken: one patient who received an MMR vaccine had taken the last MTX dose of 20 mg 42 days before vaccination, two other individuals on MTX (20-25 mg and 5 mg/week) received the YFV 91 and 106 days after the last dose was taken, another patient on ustekinumab received a YFV 143 days after the last dose; and one patient on 75 mg 6-mercaptopurine therapy took the last dose 135 days before YFV.
In BS/ZH immunosuppressed, on average, 0.6 (SD 0.7) inactivated vaccines were given at the time of live vaccine administration. In HCs, on average 0.9 (SD 1.0) inactivated vaccines were simultaneously administered (P = 0.14).
Safety assessment
Overall, 22/116 (19.0%) of patients on immunosuppressive therapy reported reactions after the vaccination (Figure 2) . Nine (7.8%) remembered local reactions, such as muscle pain or tension. Seven reactions were rated as mild; one patient with multiple sclerosis on interferon beta treatment reported a severe local reaction after a primary MMR vaccination.
Overall, 14/116 (12.2%) patients had systemic reactions: six (5.2%) had mild muscle and joint pain, four (3.5%) had flu-like symptoms, one of them with painful lymph nodes and nausea; two (1.7%) remembered fatigue, and one reported (0.9%) fever. Out of the systemic reactions, 11 were mild, two were moderate and one person with rheumatoid arthritis on treatment with sulfasalazine remembered severe muscle/joint pain after a primary YFV.
Among HCs, 15/60 (25.0%) remembered reactions after the vaccination. 7/60 (11.7%) reported local reactions, such as muscle pain, haematoma or sensitive puncture. All local reactions were mild. 8/60 (13.3%) HCs reported systemic side reactions; three (5.0%) remembered fatigue, one of them with fever. Two had (3.3%) flu-like symptoms and 4 (6.7%) had muscle/ joint pain after the vaccination. Five systemic reactions were categorized as mild and two as moderate.
There was no significant difference in percentages of local reactions and systemic reactions between controls and BS/ZH immunosuppressed (both P values = 1.0).
Likewise, severity of local and systemic reactions was comparable between the immunosuppressed and HCs. However, none of the HCs reported a severe reaction. No serious adverse event was reported.
In the five patients with 'adequate time' intervals between cessation of immunosuppressive treatment and live vaccination, only one noticed mild muscle/joint pain. None of the five patients vaccinated in the 'critical' time interval receiving long-term (≥2 weeks) high-dose-corticosteroid treatment (≥20 mg/day prednisone equivalent/day) or high-dose-MTX had side effects.
Discussion
We conducted a retrospective study in immunosuppressed travellers who received a live vaccination in three Swiss Travel Centres. We identified 197 patients on immunosuppression who were vaccinated against YF, MMR, varicella or typhoid fever and 116 could be interviewed for assessment of experienced side effects. No serious reaction was reported. Local and systemic reactions occurred as frequently in a matched HC group (25.0%) as in the immunosuppressed (19.0%).
Serious reactions due to live vaccines are extremely rare. It is estimated that a YEL-AVD (yellow fever vaccine-associated viscerotropic disease) occurs in 0.4 of 100.000 administered vaccine doses, with 1.0 per 100.000 doses in the >60-year olds and 2.3 per 100.000 administered doses in individuals aged ≥70. 45 Thus our sample was too small to detect a severe case, particularly on a specific immunosuppressive regimen and vaccine, as immunosuppressive regimens were diverse.
Moreover, according to the Swiss vaccination recommendations in patients with rheumatic diseases live vaccines are allowed on long-term (≥2 weeks) low-dose corticosteroid (<20 mg/day prednisone) non-systemic corticosteroid therapy, and methotrexate ≤20 mg/week. 18 Short-term (<2 weeks) high-dose-corticosteroid treatment (≥20 mg/day prednisone equivalent/day) is usually permitted but some experts will still wait two weeks or more before administering live vaccines. 46 As previously stated, because recommendations have been mainly based on expert opinion and lack solid data, we decided to include also travellers vaccinated on lowdose corticosteroid therapy and other generally accepted medications. In total, 65.5% of all patients observed in our study might be considered to be on a weak immunosuppressive regimen (including budesonid, glatiramer acetate, interferon, mesalazine, sulfasalazine, long-term low-dose corticosteroid and short-term high-dose-corticosteroid treatment). No difference between high or weak immunosuppressive regimen was observed with regard to percentages of side effects, local reactions, systemic reactions and severity (data not shown).
Another limitation is the rapidly increasing diversity of immunosuppressive therapies, with the consequence that our study cannot be generalized to new medications. However, as severe reactions after live vaccinations may occur more often in the immunocompromised, the paucity of data on this topic makes us believe that even small sample size studies are important to be known by practitioners in travel medicine.
Due to the retrospective study design, live vaccines were administered between 14 days and 5 years prior to the conducted interviews. Thus reduced recall on experienced vaccine reactions may have limited the obtained results. However, we believe that severe and serious reactions would have been recalled even after a 5-year time span. We additionally tried to limit recall bias by contacting age-and sex-matched HCs who had received the same vaccine during a similar time period. However, we cannot exclude that recall may differ in those with a pre-existing condition as they might have been more alert of vaccine reactions than healthy individuals.
Furthermore, it is possible that some vaccines had very serious reactions, which may even have led to death, and thus could not be reached for an interview. Nevertheless, the safety division of Swissmedic has not detected a severe infection with a vaccine strain in an immunosuppressed patient between 2001 and May 2016 (personal communication).
On the other hand, the study can give some cautious data on effectiveness. No yellow fever case was reported in the Swiss population during the relevant time span, so we can be rather sure that none of the vaccinees was diagnosed with yellow fever. However, among measles cases reported in Switzerland, we do not know how many occurred in (vaccinated) immunosuppressed persons.
Conclusion
The decision on whether live vaccines can be given to immunosuppressed patients is a daily encountered challenge by specialists of varying backgrounds. In immunosuppressed patients, liveattenuated vaccines can potentially be harmful if the vaccine strain reverts to the original pathogen and infects the vaccinated person. On the other hand these patients profit especially from these vaccinations as they are particularly vulnerable to vaccine-preventable infections. [47] [48] [49] Apart from infecting the immunosuppressed person, other vaccine-related local or systemic reactions are feared as well as re-activation of the underlying disease. By making our data on live vaccinations in immunosuppressed patients available to a wide audience our aim is to contribute to the currently scarce literature on this topic. From these additional data it is impossible to conclude that live vaccines can be safely given to immunosuppressed patients. However, despite the limitations discussed above it is reassuring that in the examined patient groups serious side effects or infections by the attenuated vaccine strain did not occur.
